1 |
Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005;22(Suppl 1):S55-S63.
|
2 |
Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010;16:2323-2330.
DOI
ScienceOn
|
3 |
Blankenhorn K, Lipson D. Business watch: 2001 in review: despite economic challenges, pharmaceutical industry still maintains steady growth. Med Mark Med 2002;37:47-62.
|
4 |
Benet LZ, Zech K. Pharmacokinetics: a relevant factor for the choice of a drug? Aliment Pharmacol Ther 1994;8(Suppl 1):S25-S32.
|
5 |
Goudie BM, McKenzie PE, Cipriano J, Griffin EM, Murray FE. Repeat prescribing of ulcer healing drugs in general practice: prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996;10:147-150.
DOI
ScienceOn
|
6 |
Boutet R, Wilcock M, MacKenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 1999;13:813-817.
DOI
ScienceOn
|
7 |
Ryder SD, O'Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ. Long term acid suppressing treatment in general practice. BMJ 1994;308:827-830.
DOI
ScienceOn
|
8 |
Hurenkamp GJ, Grundmeyer HG, Bindels PJ, Tytgat GN, Van Der Hulst RW. How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices. J Fam Pract 2002;51:241-245.
|
9 |
Rubin GP, Contractor B, Bramble MG. The use of long-term acid-suppression therapy. Br J Clin Pract 1995;49:119-120.
|
10 |
Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-453.
|
11 |
Raghunath AS, Hungin APS. Long-term prescribing of proton pump inhibitors in primary care: a cross-sectional survey. Gut 2004;53(Suppl 111):A24.
|
12 |
Prach AT, McGilchrist MM, Murray FE, Johnston DA, MacDonald TM. Prescription of acid-suppressing drugs in relation to endoscopic diagnosis: a record-linkage study. Aliment Pharmacol Ther 1999;13:397-405.
DOI
ScienceOn
|
13 |
Majumdar SR, Soumerai SB, Farraye FA, et al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 2003;98:2409-2414.
DOI
ScienceOn
|
14 |
McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010;26:624-631.
DOI
ScienceOn
|
15 |
Kim BW, Lee BI, Kim HK, et al. Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin. Korean J Gastroenterol 2009;53:84-89.
|
16 |
Attard TM, Cuffari C, Tajouri T, et al. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 2004;99:681-686.
DOI
ScienceOn
|
17 |
Bertoni G, Sassatelli R, Nigrisoli E, et al. Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis. Ital J Gastroenterol Hepatol 1999;31:192-197.
|
18 |
Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-1348.
DOI
ScienceOn
|
19 |
Carmack SW, Genta RM, Graham DY, Lauwers GY. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol 2009;6:331-341.
DOI
ScienceOn
|
20 |
Jalving M, Koornstra JJ, Gotz JM, et al. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol 2003;15:1229-1233.
DOI
ScienceOn
|
21 |
Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol 2001;158:1005-1010.
DOI
ScienceOn
|
22 |
Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000;157:747-754.
DOI
ScienceOn
|
23 |
el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997;92:1858-1860.
|
24 |
Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000;31:684-690.
DOI
ScienceOn
|
25 |
Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 2008;14:1318-1320.
DOI
ScienceOn
|
26 |
Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008;43:20-24.
DOI
ScienceOn
|
27 |
Zelter A, Fernández JL, Bilder C, et al. Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 2011;56:1743-1748.
DOI
ScienceOn
|
28 |
Kim JS, Chae HS, Kim HK, et al. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with omeprazole. Korean J Gastroenterol 2008;51:305-308.
|
29 |
Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium-and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999;13:145-153.
DOI
ScienceOn
|
30 |
Kazantsev GB, Schwesinger WH, Heim-Hall J. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Gastrointest Endosc 2002;55:600-602.
DOI
ScienceOn
|
31 |
Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion 1988;39:61-79.
DOI
ScienceOn
|
32 |
Hakanson R, Sundler F. Proposed mechanism of induction of gastric carcinoids: the gastrin hypothesis. Eur J Clin Invest 1990;20(Suppl 1):S65-S71.
|
33 |
Hakanson R, Chen D, Tielemans Y, et al. ECL cells: biology and pathobiology. Digestion 1994;55(Suppl 3):S38-S45.
|
34 |
Tielemans Y, Hakanson R, Sundler F, Willems G. Proliferation of enterochromaffinlike cells in omeprazole-treated hypergastrinemic rats. Gastroenterology 1989;96:723-729.
|
35 |
Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 1990;4:131-138.
|
36 |
Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.
DOI
ScienceOn
|
37 |
Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005;19:1610-1612.
DOI
ScienceOn
|
38 |
Waldum HL, Gustafsson B, Fossmark R, Qvigstad G. Antiulcer drugs and gastric cancer. Dig Dis Sci 2005;50(Suppl 1):S39-S44.
|
39 |
Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010;16:2323-2330.
DOI
ScienceOn
|
40 |
Diebold MD, Richardson S, Duchateau A, et al. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Dig Dis Sci 1998;43:1629-1635.
|
41 |
Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006;23:639-647.
DOI
ScienceOn
|
42 |
Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001;64:205-213.
DOI
ScienceOn
|
43 |
Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-214.
DOI
ScienceOn
|
44 |
McColl KE. Helicobacter pylori infection and long term proton pump inhibitor therapy. Gut 2004;53:5-7.
DOI
ScienceOn
|
45 |
Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-1022.
DOI
ScienceOn
|
46 |
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
DOI
ScienceOn
|
47 |
Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzag P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997;41:740-747.
DOI
ScienceOn
|
48 |
Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997;112:707-717.
DOI
ScienceOn
|
49 |
Geboes K, Dekker W, Mulder CJ, Nusteling K. Long-term lansoprazole treatment for gastro-oesophageal reflux disease:clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001;15:1819-1826.
DOI
ScienceOn
|
50 |
Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S. Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastroenterol 2000;6:789-792.
|
51 |
Uemura N, Okamoto S, Yamamoto S, et al. Changes in Helicobacter pyloriinduced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 2000;14:1345-1352.
DOI
ScienceOn
|
52 |
Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial. Gut 2004;53:12-20.
DOI
ScienceOn
|